Mixed Plasmodium falciparum & Plasmodium vivax drug resistant malaria: challenge in diagnosis and therapy

Pratista Adi and Heri Sutanto

Abstract

Over decades, Plasmodium has developed against all antimalarial drugs, such as: chloroquine, sulphadoxine-pyrimethamine, quinine, piperaquine and mefloquine. More recently, resistance to arthemisin derivates was reported, resulting failure of arthemisin-based combination therapy (ACT). It is life threatening disease and emerging in many regions, increasing in geographic range. We report the case of 40-year Asian man, who presented with recurrent malaria infection. He was a soldier who frequently travel to malaria endemic area of Indonesia. Firstly, he was infected by Plasmodium vivax in 2007, but clinically manifested 6 years later. The next infection was in 2013 with the same species, got ACT plus primaquine and microscopically cured. He clinically manifested with vivax malaria for 4x, with all manifested in the time he moved out from endemic area. We called it premunition, a host response that protect against high number of parasite and illness without eliminating the infection. In the 4th infection, he manifested with 12-hourly fever, which is unmatched with microscopic finding that show Plasmodium vivax. In the 3rd day of evaluation, we found Plasmodium falciparum in the blood smear, suggesting mixed infection. We wondered if there was resistance to- or suboptimal dose of antimalarial drugs that may cause failure of therapy in this patient. In our source-limited hospital, where molecular examination could not be done, we give him second line therapy and highlight the emerging condition of drug resistant malaria in our country. This case focuses on clinical approach of drug resistant malaria in source-limited region, report to global data and prompting call for new treatment.